OtherArticle
Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect
Junichi Enokizono, Hiroyuki Kusuhara and Yuichi Sugiyama
Drug Metabolism and Disposition November 8, 2006, DOI: https://doi.org/10.1124/dmd.106.012567
Junichi Enokizono
Hiroyuki Kusuhara
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
OtherArticle
Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect
Junichi Enokizono, Hiroyuki Kusuhara and Yuichi Sugiyama
Drug Metabolism and Disposition November 8, 2006, DOI: https://doi.org/10.1124/dmd.106.012567
OtherArticle
Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect
Junichi Enokizono, Hiroyuki Kusuhara and Yuichi Sugiyama
Drug Metabolism and Disposition November 8, 2006, DOI: https://doi.org/10.1124/dmd.106.012567
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement